Winton Group’s Avita Medical RCEL Stock Holding History

Winton Group’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,523	Closed	-$158K	–	829
2023 Q4	$158K	Buy	+11,523	New	+$132K	0.01%	665

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Winton Group's RCEL Position: Q1 2024 in Review

Winton Group sold out of Avita Medical (RCEL) in Q1 2024, closing a stake of 11,523 shares — an estimated $158K sold.

Winton Group first reported a position in RCEL in Q4 2023 and held it in 1 quarter. The position peaked at $158K in Q4 2023. 82 funds tracked by Wall St. Rank hold RCEL as of Q1 2024.

Winton Group reported no remaining Avita Medical position as of Q1 2024 after selling out during the quarter.
Winton Group sold 11,523 Avita Medical shares in Q1 2024, an estimated $158K.
Winton Group first reported a position in Avita Medical in Q4 2023 and held it in 1 quarter.
Winton Group's Avita Medical position peaked at $158K in Q4 2023.
82 funds tracked by Wall St. Rank held Avita Medical as of Q1 2024.

Based on Winton Group's 13F filing for Q1 2024, filed 14 May 2024.